Top VA in-vitro diagnostic substance manufacturing contractors
In the 12 months ending Oct 5, 2026, the Department of Veterans Affairs obligated $105.5M in net prime contract dollars under NAICS 325413, down 12.1% from $120.0M in the preceding 12 months. 71 prime contractors received positive obligations, and 8 of them accounted for 80% of that spend.
Prime contracts funded by the Department of Veterans Affairs. Latest 12 months: Oct 6, 2025 to Oct 5, 2026. Source: USAspending.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year (October to September).
Top VA contractors for NAICS 325413
Ranked by positive obligations in the latest 12 months. Share is of all positive obligations in this market.
| # | Contractor | Latest 12 mo | Prior 12 mo | Share | Rank change |
|---|---|---|---|---|---|
| 1 | Biomerieux Inc | $31.1M | $33.7M | 28.9% | ▲ 1 |
| 2 | Cepheid | $27.7M | $35.4M | 25.7% | ▼ 1 |
| 3 | Roche Diagnostics Corporation | $12.8M | $10.1M | 11.8% | — |
| 4 | Quest Diagnostics Incorporated | $4.4M | $4.3M | 4.1% | — |
| 5 | Fisher Scientific Company L.L.C. | $4.1M | $2.9M | 3.8% | ▲ 1 |
| 6 | Abbott Laboratories Inc. | $3.3M | $4.0M | 3.0% | ▼ 1 |
| 7 | Werfen USA LLC | $2.0M | $2.4M | 1.8% | — |
| 8 | Becton, Dickinson and Company | $1.9M | $1.1M | 1.8% | ▲ 8 |
| 9 | Beckman Coulter, Inc | $1.6M | $667K | 1.5% | ▲ 13 |
| 10 | Binding Site, Inc., the | $1.4M | $1.1M | 1.3% | ▲ 4 |
| 11 | One Lambda, Inc. | $1.3M | $1.2M | 1.2% | — |
| 12 | Ortho-Clinical Diagnostics, Inc | $1.2M | $1.2M | 1.1% | — |
| 13 | Government Scientific Source Inc | $1.1M | $1.6M | 1.0% | ▼ 5 |
| 14 | Diasorin Inc | $1.0M | $1.3M | 1.0% | ▼ 4 |
| 15 | Qiagen, LLC | $923K | $1.1M | 0.9% | — |
What changed in the last 12 months
Contractors with the largest change in reported obligations versus the preceding 12 months.
Largest gains
- Roche Diagnostics Corporation$10.1M → $12.8M (+$2.6M) · now #3
- Fisher Scientific Company L.L.C.$2.9M → $4.1M (+$1.2M) · now #5
- Beckman Coulter, Inc$667K → $1.6M (+$961K) · now #9
Largest declines
- Cepheid$35.4M → $27.7M (−$7.7M) · now #2
- Biomerieux Inc$33.7M → $31.1M (−$2.6M) · now #1
- Hologic, Inc.$825K → −$881K (−$1.7M) · no latest-period obligations
New to this market
9 contractors received their first obligations in this market (since FY2022) during the latest 12 months. The largest:
| Contractor | First obligation | Latest 12 mo |
|---|---|---|
| First Nation Group LLC | Apr 28, 2026 | $227K |
| Advanced Instruments LLC | Dec 30, 2025 | $194K |
| Asem Solutions LLC | Mar 18, 2026 | $94K |
| Laboratory Corporation of America | May 29, 2026 | $75K |
| LGC Clinical Diagnostics Inc | Jan 15, 2026 | $74K |
| Euroimmun US Incorporated | Oct 27, 2025 | $54K |
| Promega Corporation | Jun 1, 2026 | $49K |
| Electromedical Products International, Inc. | Mar 12, 2026 | $37K |
Where the money comes from
Funding sub-agencies within the Department of Veterans Affairs, latest 12 months. The funding organization can differ from the office that runs the requirement.
| Funding sub-agency | Latest 12 mo | Prior 12 mo | Change |
|---|---|---|---|
| Department of Veterans Affairs | $105.5M | $120.0M | Down $14.6M (12.1%) |
Potential recompetes
Large awards in this market whose current period of performance ends in the next 18 months. Treat these as research leads: options, extensions, and follow-on vehicles often change the timing.
| Award | Incumbent | Obligated | Current end |
|---|---|---|---|
| 36C25726N0164 | Cepheid CEPHEID REAGENTS CONTRACT - ORDERING PERIOD 1 | $1.6M | Dec 21, 2026 |
| 36C24826N0280 | Biomerieux Inc MOLECULAR PATHOGEN DETECTION | $2.5M | Jan 12, 2027 |
| 36C24722P0546 | Roche Diagnostics Corporation COBAS 6800 COST PER TEST KITS | $1.8M | Mar 9, 2027 |
| 36C24822F0151 | Abbott Molecular Inc. INFECTIOUS DISEASE PCR REAGENTS AND CONSUMABLES | $3.2M | Mar 31, 2027 |
| 36C26226P0733 | Cepheid COVID REAGENTS | $2.0M | Apr 1, 2027 |
| 36C26022P0781 | Cepheid MOLECULAR DIAGNOSTIC TESTING SYSTEM LEASE AND PURCHASE OF INSTRUMENT SPECIFIC ASSAYS | $2.7M | Jul 31, 2027 |
| 36C25526N0337 | Cepheid IN-VITRO REAGENTS - VISN 15, ORDERING PERIOD TWO | $2.6M | Jul 31, 2027 |
| 36C25722C0078 | Cepheid NEW CEPHEID | $2.8M | Aug 31, 2027 |
| 36C24824P0028 | Roche Diagnostics Corporation HISTOLOGY CPT | $3.2M | Sep 30, 2027 |
| 36C24827N0001 | Abbott Laboratories Inc. AUTOMATED CHEMISTRY LABORATORY COST PER TEST | $1.9M | Sep 30, 2027 |
Common questions
Who are the top VA contractors for NAICS 325413?
In the latest 12 months, Biomerieux Inc ($31.1M), Cepheid ($27.7M), Roche Diagnostics Corporation ($12.8M) received the most VA obligations for in-vitro diagnostic substance manufacturing.
How concentrated is this market?
The eight largest primes held 81.0% of positive obligations, and Biomerieux Inc alone held 28.9%. 9 contractors won their first obligations in this market during the latest 12 months.
Are any large VA NAICS 325413 contracts ending soon?
10 of the largest awards in this market reach their current end date in the next 18 months. The first is 36C25726N0164 (Cepheid, $1.6M obligated), ending Dec 21, 2026. An end date is a research lead, not a confirmed recompete: options and extensions often move it.
Related markets
NAICS 325413 across all agencies
DoD · NAICS 325413
$50.8MHHS · NAICS 325413
$12.0MFigures are net obligations on prime contracts (award types A–D) from USAspending.gov, grouped by funding agency and the NAICS code on each award. Net obligations include deobligations and corrections, so they can differ from positive-obligation totals. See methodology.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.